For the quarter ended September 2024, Supernus Pharmaceuticals (SUPN) reported revenue of $175.69 million, up 14.2% over the same period last year. EPS came in at $1.06, compared to -$0.29 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $155.06 million, representing a surprise of +13.30%. The company delivered an EPS surprise of +171.79%, with the consensus EPS estimate being $0.39.While investors closely watch year-over-year changes in headline numbers -- revenue an ...